Home › Therapeutic areas › Neurology › Rett Syndrome
Rett Syndrome (3 companies)
Companies with an active program in Rett Syndrome.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| NGNE | Neurogene | Neurology Rare | 1 | Phase 3 | $506M | 1 |
| PRQR | ProQR Therapeutics | MetabolicNeurology Rare | 1 | Phase 1 | $191M | 7 |
| TSHA | Taysha Gene Therapies | Neurology Rare | 1 | Phase 3 | $1.41B | 4 |
No companies match.